Health Care

Analyst EPS Forecast Highlights: Novo Nordisk A/S (NYSE:NVO)

0 13

Novo Nordisk A/S (NYSE:NVO) dropped -0.26% and closed the trade at $ 46.12. The company recorded a trading capacity of 1.45 million shares below its three months average daily volume of 2.35 million shares. During the last trade, shares reached to high price of $46.55 and touched the low price of $46.00. The stock’s 50-day moving average is noted at $48.91 and its 200-day moving average is stands at $53.35.

Additionally, the company has a PE ratio of 21.57 and has EPS of 2.14. The company has market capitalization of $116.97B.

Currently Novo Nordisk A/S (NVO) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “12″ Analysts”. “3” rated “Sell” for the company. “14” said the company as a “Hold”. Overweight rating was given by “3” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $55.01 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $69.22 however minimum price target advised by analysts is $44.68. The Median price target for the stock is measured at $53.82.

Presently, Analysts decided consensus EPS estimate of $0.57 for present quarter and one month ago projected EPS estimate was at $0.57. If we take a look at back 3 month ago, consensus EPS estimate was $0.59.

A current consensus EPS estimate for next quarter is at $0.55 and 3 month ago EPS forecast was $0.59. Have a look at back 1 month ago, consensus EPS forecast was seen at $0.55.

For current fiscal year, most recent EPS estimate is set at $2.27 based on Analyst consensus and three month ago consensus EPS opinions was at $2.34. During period one month ago, consensus EPS forecast was decided at $2.27.

A current consensus EPS projection for next fiscal year is observed at $2.49 and one month ago consensus EPS forecast was at $2.50. Take a look at back three month ago, consensus EPS estimate opinions was decided at $2.60 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 11 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 3. 14 advised the “Hold” rating about this stock. 4 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 15 said a “Buy Rating” and 1 announced “Overweight Rating”. 13 advised “Hold Rating” regarding the stock. 4 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.